As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months that create a COI.
Additionally, PER® is required by ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multi-step process.
Faculty and Staff Disclosure
The following individuals have no relevant financial relationships with commercial interests to disclose:
Jorge E. Gomez, MD and Natasha B Leighl, BSc, MD, MSc.
The staff of Physicians' Education Resource®, LLC: Leigh Anne Bongiovanni; Ann C. Lichti, CCMEP; Dru Dace, PhD; and Megan O'Connell.
The following individuals have relevant financial relationships with commercial interests to disclose:
Abraham Chachoua, MD —Speaker’s Bureau: Eli Lilly; Richard J. Gralla, MD —Consultant: Eisai; Eli Lilly; Helsinn; Merck; Other Support: Lectures sponsored by Eisai; Helsinn; Merck; Balazs Halmos, MD —Grant/Research Support: Eli Lilly; Roche; Astex; Daiichi; Boehringer-Ingelheim; Bristol-Myers-Squibb; Merck; Astra-Zeneca; Oncothyreon; Astellas; Pfizer; Mirati; Harry D. Harper, MD – Speaker’s Bureau: Eli Lilly; Mark G. Kris, MD —Grant/Research Support: Pfizer Inc.; POMA; Boehringer-Ingelheim; Consultant: Novartis Pharmaceuticals Corporation; Pfizer Inc.; Genentech/Roche; Boehringer-Ingelheim; Benjamin P. Levy, MD —Consultant: Genentech; Pfizer Inc.; Speaker’s Bureau: Eli Lilly; Genentech; Pfizer Inc.; Roman Perez-Soler, MD —Speaker’s Bureau: Eli Lilly; Genentech; Bilal Piperdi, MD —Consultant: Amgen; Speaker’s Bureau: Genentech/Roche; Celgene Corporation; Merck; Pfizer, Inc.; Harry Raftopoulos, MD — Grant/Research Support: Novartis Pharmaceuticals Corporation; Roche; Pfizer Inc.; Eisai; Consultant: Merck; Gregory J. Riely, MD, PhD —Grant/Research Support: Chugai/Roche; Infinity; Pfizer; Novartis; Merk; Millennium; Consultant: Ariad; Naiyer A. Rizvi, MD —Grant/Research Support: Bristol-Myers-Squibb; Roche/Genentech; Medimmune; Merck; Consultant: Bristol-Myers-Squibb; Roche/Genentech; Medimmune; Charles M. Rudin, MD, PhD —Consultant: Celgene Corporation; Bryan J. Schneider, MD —Grant/Research Support: Celgene Corporation; Eli Lilly; Boehringer-Ingelheim; Consultant: Genentech; Speaker’s Bureau: Genentech; Pfizer Inc.; Alice T. Shaw, MD, PhD —Consultant: Pfizer Inc.; Novartis Pharmaceuticals Corporation; Ariad; Genentech; Steven E Vogl, MD —Stock/Shareholder: Amgen; Bristol-Myers-Squibb; Other Support: Advisory Board Celgene Corporation
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY